- Home
- TAC vs ACLX Comparison
TAC vs ACLX Comparison
Compare TAC & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- ACLX
- Stock Information
- Founded
- TAC 1909
- ACLX 2015
- Country
- TAC Canada
- ACLX United States
- Employees
- TAC N/A
- ACLX N/A
- Industry
- TAC Electric Utilities: Central
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- TAC Utilities
- ACLX Health Care
- Exchange
- TAC Nasdaq
- ACLX Nasdaq
- Market Cap
- TAC 4.3B
- ACLX 4.4B
- IPO Year
- TAC N/A
- ACLX 2022
- Fundamental
- Price
- TAC $17.26
- ACLX $85.09
- Analyst Decision
- TAC Strong Buy
- ACLX Strong Buy
- Analyst Count
- TAC 4
- ACLX 12
- Target Price
- TAC $21.63
- ACLX $113.08
- AVG Volume (30 Days)
- TAC 2.5M
- ACLX 548.8K
- Earning Date
- TAC 11-06-2025
- ACLX 11-07-2025
- Dividend Yield
- TAC 1.04%
- ACLX N/A
- EPS Growth
- TAC N/A
- ACLX N/A
- EPS
- TAC N/A
- ACLX N/A
- Revenue
- TAC $1,838,165,207.00
- ACLX $56,979,000.00
- Revenue This Year
- TAC N/A
- ACLX N/A
- Revenue Next Year
- TAC N/A
- ACLX $210.73
- P/E Ratio
- TAC N/A
- ACLX N/A
- Revenue Growth
- TAC N/A
- ACLX N/A
- 52 Week Low
- TAC $7.82
- ACLX $47.86
- 52 Week High
- TAC $17.69
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- TAC 76.45
- ACLX 54.28
- Support Level
- TAC $16.24
- ACLX $82.64
- Resistance Level
- TAC $17.10
- ACLX $94.07
- Average True Range (ATR)
- TAC 0.65
- ACLX 3.64
- MACD
- TAC 0.04
- ACLX -0.81
- Stochastic Oscillator
- TAC 86.20
- ACLX 21.43
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.